AFALIEVA 30 mg contains Afatinib, an oral irreversible ErbB family tyrosine kinase inhibitor (TKI). It covalently inhibits EGFR (ErbB1) and HER2 (ErbB2) receptors, blocking downstream signaling pathways involved in tumor cell growth and survival. It is effective in EGFR mutation–positive lung cancers.

Afatinib is used for:

   1. Metastatic Non-Small Cell Lung Cancer (NSCLC)
       – With EGFR exon 19 deletion or exon 21 (L858R) substitution mutations

   2. Squamous Cell Carcinoma of Lung
       – After failure of platinum-based chemotherapy (selected cases)

Common side effects:

     •  Diarrhea

     •  Acneiform rash

     •  Stomatitis / mouth ulcers

     •  Paronychia

     •  Dry skin

Serious side effects:

     •  Severe diarrhea with dehydration

     •  Interstitial lung disease (rare)

     •  Hepatotoxicity

 Early dose modification helps prevent complications.

Usual adult dose:

      •  40 mg once daily

30 mg strength is commonly used for dose reduction due to intolerance.


NOTE: This medicine should be taken only under a doctor’s supervision.